Head of Research centre

Slides:



Advertisements
Similar presentations
Cindy Powers Magrini, PharmD, BCPS
Advertisements

Mady Chalk, PhD., MSW Treatment Research Institute November, 2013.
2 emcdda.europa.eu European drug report package A comprehensive analysis on the drugs problem in Europe.
Models of Harm Reduction
Swinomish Wellness Program
Workforce development in the new Annette Dale- Perera Strategic Director of Addiction and Offender Care.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence April 2008.
John R. Kasich, Governor Tracy J. Plouck, Director Andrea Boxill, Deputy Director Andrea Boxill, Deputy Director Governor’s Cabinet Opiate Action Team.
Drug use, related problems and interventions targeting drug users in prison in the European countries: main issues and challenges for the future Linda.
Substitution Treatment for Opiate Dependence in Europe Annette Verster Montego Bay August 2001.
 Insufficient Reliable data in this region  Estimated people living with HIV  The number of new HIV infections in the region increased.
HIV and drug prevention in Estonia Harm reduction services
An EMCDDA view on recovery Roland Simon Head of Unit Intervention, Best Practice, and Scientific Partners.
Essential elements for regulation Bylaw on drug demand reduction.
Integrated Health Home Services in an Opioid Treatment Program: A Model Yngvild Olsen, MD, MPH Institutes for Behavior Resources, Inc./REACH Health Services.
HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania Signe ROTBERGA UNODC, Baltic States 5 November.
Recommendations on the Management of Opioid Overdose Ruth Birgin.
HARM REDUCTION RESPONSES TO DRUGS IN THE EUROPEAN UNION – FROM MARGIN TO MAINSTREAM 8 th Annual Meeting of the European Red Cross / Red Crescent Network.
Annual report 2010: the state of the drugs problem in Europe.
Opioid addiction treatment: Challenges (and opportunities) for community practice Marc Fishman MD.
Brian Emerson Medical Consultant, Population and Public Health Division BC Ministry of Health
If I ruled the world… Presentation to Prisons and Beyond NOMS Prison Drug Strategy Unit, in association with the Federation of Drug & Alcohol Professionals.
The British vs. American Models in history Drug addiction is illness Drug addiction is illness Medical model: based on controlled dispensation of drugs.
On demand services – Results from a low- threshold- Buprenorphine/Naloxone program (LASSO) Jon-Aksel Jacobsen and Peter Krajci Oslo Municipality and Oslo.
Module 1 General introduction to substitution treatment.
Pennsylvania: The State of HCV 2015
EU model – evidence based Out of 100% of people who tried drugs, only 10% get to chronicle stage Out of 100% of people who tried drugs, only 10% get to.
Naloxone nasal spray in Norway Thomas Clausen Professor (Dr. med) 5. November 2015.
BEST PRACTICE PORTAL BEST PRACTICE PORTAL project presentation to the Scientific Committee Ferri et al Lisbon, 16th July 2010.
THE 6 TH NATIONAL SCIENTIFIC CONFERENCE ON HIV/AIDS State of the art and new perspectives in drug addiction treatment Dr L Michel, MD, PhD Inserm U1178.
Focus on Addictions and Homelessness Catriona Ritchie NHSGGC Addictions Services GP ST 1+2 Teaching – Deprivation Related Problems in General Practice.
The Prescription Opioid & Heroin Crisis: Addiction & Medication Assisted Treatment Andrew Kolodny, M.D. Chief Medical Officer, Phoenix House Foundation.
Suboxone and Opioid Trends Joseph Merrill M.D., M.P.H. University of Washington June 16, 2009.
Responding to the Opioid Addiction Epidemic Andrew Kolodny, M.D. Chief Medical Officer, Phoenix House Foundation Inc. Executive Director, Physicians for.
Deadly trio: mental health – HIV - drugs
MODULE 3 Harm reduction advocacy
The Highs and Lows of Relapse and Recovery in Opioid Use Disorder
Cascade of care for people who use drugs - opportunities for integration and scale up of harm reduction services and other evidence based interventions.
OPIOID EPIDEMIC.
Illinois’ 1115 Behavioral Health Transformation Waiver
6% of adults had used one or more illicit drugs in last 12 months.
Medication-Assisted Therapy at Coleman Profession Services
COLLECTIVE IMPACT APPROACH TO ADDRESSING
An overdose Reduction PlaN
McLean Hospital Division of Alcohol and Drug Abuse
Addressing Drug Use Together Through a Health Based Approach:
No one gets left behind: Addressing the hidden burden of hepatitis C related advanced liver disease in PWID in the community John S Lambert, MD, PhD.
Opioid Crisis A Call to ACTION
Experiences from a national overdose prevention strategy: Nasal naloxone distribution and lessons learned Philipp Lobmaier, MD, PhD Norwegian Centre.
Nick Szubiak, MSW, LCSW Director, Clinical Excellence in Addictions
Jonathan Mermin, MD, MPH RADM, USPHS
A State Targeted Response to the Opioid Crisis:
Mortality during Opioid Maintenance Treatment in Norway in the years 2014 and 2015 Anne Bech1, Thomas Clausen2, Helge Waal2,3, Ivar Skeie4,2 Norwegian.
National Programme for limiting spread of HIV/AIDS in Latvia 2008–2012
Primary Prevention in the Time of the Opioid Epidemic
Opioid-related harms and responses
The HIV Epidemic among People who Inject Drugs
Pain Management and Substance Use Disorders: JCPP Strategic Session
Impact of Policy and Regulatory Responses to the Opioid Epidemic on the Care of People with Serious Illness Hemi Tewarson, Director, Health Division National.
German Drug and Addiction Policy
Terje P. Hagen Department of Health Management and Health Economics,
buprenorphine-naloxone
Relative risks of clinical events for primary and secondary prevention with selected drugs Thomas A Gaziano, et al. Lancet 2006; 368:
Town of Collingwood Council September 10th, 2018 Mia Brown RN BScN
The relationship between incarceration and opioid addiction treatment
Suzanne Carlberg-Racich, MSPH, PHD
No conflicts of interest
Strategic Initiatives to Address Opioid Overdose & Addiction
Human Dignity and Harm Reduction
Medication Assisted Treatment of Opioid Use Disorder
Presentation transcript:

Head of Research centre Preventing drug-related deaths: Policy implications and ways forward. Focus on Norway. Thomas Clausen Head of Research centre Professor (MD, PhD) thomas.clausen@medisin.uio.no October 26th, 2017 Lisbon

Conflicts of interest None Thomas Clausen is a full-time employee at the Norwegian Centre for Addiction Research, University of Oslo, Norway

Agenda Overdose deaths and the Norwegian picture Effective strategies

The Nordic region Sweden Denmark Finland Norway Iceland Populations 9.9mill 5.7mill 5.5 mill 5.3 mill 0.3 mill ODs per 1 mill 101 58 43 76 100+? Numbers in OMT 3 700 6300 3000 7 500 120 Universal health care systems Treatment free of charge, for the patient Public health approaches; population based measures of prevention Access to treatment and harm-reduction measures; high Opioid maintenance treatment provided (50+% of target pop.) Norway; Mean age at overdose death; 43 yrs; on a rise EMCDDA 2017

Treatment and service provision Larney et al, Lancet Glob Health, 2017

Overdose deaths, Norway 289 54 2015 http://www.fhi.no/artikler/?id=117255 Norwegian Institute of Public health

Overdose deaths and OMT; Norway Numbers in OMT Burden of disease report 2016; Norway; FHI

Overdoses in the Nordics; (2012)

Opioid using persons A wider range of subpopulations

The situation and challenges An ageing cohort of heroin users Polydrug injectors; now 50%+ in OMT High somatic and mental health burdens AND New populations using opioids Chronic pain patients NPS users (fentanyl) Most current interventions targeted towards «heroin users» Overdose deaths outside of treatment & somatic causes of deaths in treatment

Norwegian National Overdose Strategy 2014 – 2017 Sure you can quit drugs - but first you have to survive! https://helsedirektoratet.no/Lists/Publikasjoner/Attachments/145/National-overdose-strategy-2014-2017-IS-0418EN.pdf

National overdose prevention strategy Aims at reducing numbers of deaths annually Long-term 0-vision Multidimensional strategy: Improve access to evidence based treatment (OMT) Take-home Naloxone distribution Encourage “SWITCH” from injection to inhalation Improve knowledge and practices in municipalities Included funding (also for evaluation)

Overdose deaths, Norway OMT Naloxone Less inject Population NPS Prescr. op. Ageing Widespread Analytic mt Cohort eff http://www.fhi.no/artikler/?id=117255

Opioid using persons A heterogenous group Outside of treat. Residential long-term In prison Naltrexone Harm reduction OMT

Opioid Drug treatment A comprehensive model Voluntary Tapering off OMT Syringe exchange Low-threshold-OMT Abstinence oriented treatment AO User room OMT Buprenorphine – Methadone Heroin Stable Abstinence Stabilizing Harm reduction ACT Dual diagnosis clinics Compulsory treatment Abstinence oriented in prison OMT in prison From; Wim van den Brink Compulsory

A systematic approach A range of services Treatment goals: Coordinated - A treatment system Integrated - Cater for comorbidities Tailored to needs - Primarily in community Long-term - Varying intensity Treatment goals: Reduced risk Improved health Improved quality of life

Waves of opioid epidemic A moving target